These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1160 related articles for article (PubMed ID: 33581644)
1. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644 [TBL] [Abstract][Full Text] [Related]
2. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade. Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694 [TBL] [Abstract][Full Text] [Related]
3. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846 [No Abstract] [Full Text] [Related]
6. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434 [TBL] [Abstract][Full Text] [Related]
7. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer. Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259 [TBL] [Abstract][Full Text] [Related]
9. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576 [TBL] [Abstract][Full Text] [Related]
10. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995 [TBL] [Abstract][Full Text] [Related]
11. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model. Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors. Wei M; Zuo S; Chen Z; Qian P; Zhang Y; Kong L; Gao H; Wei J; Dong J Front Immunol; 2022; 13():1017574. PubMed ID: 36451817 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139 [TBL] [Abstract][Full Text] [Related]
14. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy. Wang S; Li Y; Xu C; Dong J; Wei J J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640 [TBL] [Abstract][Full Text] [Related]
15. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389 [TBL] [Abstract][Full Text] [Related]
17. Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL Front Immunol; 2021; 12():610042. PubMed ID: 33679747 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991 [TBL] [Abstract][Full Text] [Related]
19. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity. Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860 [TBL] [Abstract][Full Text] [Related]
20. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment. Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]